203 related articles for article (PubMed ID: 21745498)
21. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
22. Role of MRI in screening women at high risk for breast cancer.
Lehman CD
J Magn Reson Imaging; 2006 Nov; 24(5):964-70. PubMed ID: 17036340
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
[TBL] [Abstract][Full Text] [Related]
24. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
25. Five-year analysis of magnetic resonance imaging as a screening tool in women at hereditary risk of breast cancer.
Kam JK; Naidu P; Rose AK; Mann GB
J Med Imaging Radiat Oncol; 2013 Aug; 57(4):400-6. PubMed ID: 23870334
[TBL] [Abstract][Full Text] [Related]
26. Screening women at increased risk with MRI.
Boetes C; Veltman J
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S10-5. PubMed ID: 16361123
[TBL] [Abstract][Full Text] [Related]
27. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
28. Update on screening breast MRI in high-risk women.
Boetes C
Magn Reson Imaging Clin N Am; 2010 May; 18(2):241-7, viii. PubMed ID: 20494309
[TBL] [Abstract][Full Text] [Related]
29. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk.
Podo F; Sardanelli F; Canese R; D'Agnolo G; Natali PG; Crecco M; Grandinetti ML; Musumeci R; Trecate G; Bergonzi S; De Simone T; Costa C; Pasini B; Manuokian S; Spatti GB; Vergnaghi D; Morassut S; Boiocchi M; Dolcetti R; Viel A; De Giacomi C; Veronesi A; Coran F; Silingardi V; Turchett D; Cortesi L; De Santis M; Federico M; Romagnoli R; Ferrari S; Bevilacqua G; Bartolozzi C; Caligo MA; Cilotti A; Marini C; Cirillo S; Marra V; Martincich L; Contegiacomo A; Pensabene M; Capuano I; Burgazzi GB; Petrillo A; Bonomo L; Carriero A; Mariani-Costantini R; Battista P; Cama A; Palca G; Di Maggio C; D'Andrea E; Bazzocchi M; Francescutti GE; Zuiani C; Londero V; Zunnui I; Gustavino C; Centurioni MG; Iozzelli A; Panizza P; Del Maschio A
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):115-24. PubMed ID: 12585665
[TBL] [Abstract][Full Text] [Related]
30. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
[TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer.
Riedl CC; Ponhold L; Flöry D; Weber M; Kroiss R; Wagner T; Fuchsjäger M; Helbich TH
Clin Cancer Res; 2007 Oct; 13(20):6144-52. PubMed ID: 17947480
[TBL] [Abstract][Full Text] [Related]
32. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
33. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.
Kuhl C; Weigel S; Schrading S; Arand B; Bieling H; König R; Tombach B; Leutner C; Rieber-Brambs A; Nordhoff D; Heindel W; Reiser M; Schild HH
J Clin Oncol; 2010 Mar; 28(9):1450-7. PubMed ID: 20177029
[TBL] [Abstract][Full Text] [Related]
34. The use of magnetic resonance imaging in breast cancer screening.
Lee CH; Weinreb JC
J Am Coll Radiol; 2004 Mar; 1(3):176-82. PubMed ID: 17411555
[TBL] [Abstract][Full Text] [Related]
35. High-risk screening: multi-modality surveillance of women at high risk for breast cancer (proven or suspected carriers of a breast cancer susceptibility gene).
Kuhl CK
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):103-6. PubMed ID: 12585663
[TBL] [Abstract][Full Text] [Related]
36. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
[TBL] [Abstract][Full Text] [Related]
37. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.
Kuhl CK; Schrading S; Leutner CC; Morakkabati-Spitz N; Wardelmann E; Fimmers R; Kuhn W; Schild HH
J Clin Oncol; 2005 Nov; 23(33):8469-76. PubMed ID: 16293877
[TBL] [Abstract][Full Text] [Related]
38. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer.
Haroun I; Graham T; Poll A; Sun P; Hill K; Weitzner E; Narod S; Warner E
Breast; 2011 Jun; 20(3):254-8. PubMed ID: 21306899
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer screening in women: An integrative literature review.
Ravert PK; Huffaker C
J Am Acad Nurse Pract; 2010 Dec; 22(12):668-73. PubMed ID: 21129075
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study.
Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
